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AbstrACt
Objective To explore the clinical pathways, including 
signs and symptoms, and symptom progression patterns 
preceding idiopathic pulmonary fibrosis (IPF) diagnosis.
Design and setting A historical cohort study was 
conducted using primary care patient records from the 
Optimum Patient Care Research Database.
Participants Patients included were at least 30 years, 
had IPF diagnosis, identified via clinical- coding and free- 
text records and had a consultation with a chest specialist 
prior to IPF diagnosis.
Outcome measures The signs and symptoms in the 
year prior to IPF diagnosis from clinical codes and free- 
text in primary care electronic records included: cough, 
dyspnoea, dry cough, weight loss, fatigue/malaise, loss of 
appetite, crackles and clubbed fingers. The time course of 
presentations of clinical features and investigations in the 
years prior to IPF diagnosis were mapped.
results Within 462 patients identified, the majority 
(77.9%) had a respiratory consultation within 365 days 
prior to the chest specialist visit preceding the IPF 
diagnosis recorded in their primary care records. The 
most common symptoms recorded in the 1 year prior to 
IPF diagnosis were dyspnoea (48.7%) and cough (40.9%); 
other signs and symptoms were rarely recorded (<5%). 
The majority of patients with cough (58.0%) and dyspnoea 
(55.0%) in the 1 year before IPF diagnosis had multiple 
recordings of the respective symptoms. Both cough and 
dyspnoea were recorded in 23.4% of patients in the year 
prior to diagnosis. Consultation rates for cough, dyspnoea 
and both, but not other signs or symptoms, began to 
increase 4 to 5 years prior diagnosis, with the sharpest 
increase in the last year. Cough and dyspnoea were often 
preceded by a reduction in measured weight over 5 years 
leading to IPF diagnosis.
Conclusion Prolonged cough and/or progressive 
dyspnoea, especially if accompanied with weight loss, 
should signal for a referral to specialist assessment at the 
earliest opportunity.
IntrODuCtIOn
Idiopathic pulmonary fibrosis (IPF) is the 
most common and most lethal of the idio-
pathic interstitial pneumonias, estimated 
to affect 14 to 43 per 100 000 population, 
typically over the age of 50.1–3 Patients with 
IPF have a very poor prognosis, with median 
years of survival of only 2.5 to 3.5 years and 
5- year survival rate as low as 20%.4 5 In the 
UK, the mortality rate for IPF was reported 
to be 5.10 per 100 000 person- years in 2005 
to 2008, increasing by around 5% per year 
since 1968,6 thus signifying a significant and 
growing healthcare concern.
Diagnosing IPF in primary care is chal-
lenging due to the non- specific features in 
the early stages of the disease,7 and IPF is 
seldom seen by physicians in primary care.8 
In secondary care, a confident diagnosis 
requires expertise from a multidisciplinary 
team of pulmonologists, radiologists and 
strengths and limitations of this study
 ► This was the first study to map clinical progression 
patterns in the years leading to idiopathic pulmonary 
fibrosis (IPF) diagnosis.
 ► We used a large primary care database with data 
available up to 7 years prior to IPF diagnosis and re-
cords of patients’ secondary care usage.
 ► We developed a list of relevant clinical features via 
initial review of patient records, allowing for identi-
fication of less common clinical features which may 
be used to find patterns of symptoms to potentially 
aid IPF diagnosis.
 ► A very specific definition of IPF was used in this 
study requiring specialist consultation and diagno-
sis of IPF in primary care after the consultation. This 
may result in the exclusion of cases where there 
was no primary care record indicating specialist 
consultation.
 ► Coding limitations of a database that was designed 
for clinical practice rather than research, are a weak-
ness. However, we used both symptom coding and 
free- text data to identify IPF, and clinical features in-
dicative of IPF, increasing detection sensitivity.
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pathologists.9 10 Identification of early predictors and 
clinical patterns leading to subsequent IPF diagnosis 
may help primary care physicians identify potential IPF 
patients for further examination and guide appropriate 
referral to specialist respiratory services.
Treatment of IPF had previously been limited to 
symptom management and palliation, but two anti-
fibrotic drugs, pirfenidone and nintedanib,11 12 have 
recently become available. Both treatments may improve 
IPF disease outcomes13–16 and are recommended by the 
UK National Institute for Health and Care Excellence17 18 
and by the American Thoracic Society (ATS)/ European 
Respiratory Society (ERS)/ Japanese Respiratory Society 
(JRS)/ Latin American Thoracic Association (LATA) 
clinical practice guideline.19 To obtain optimal benefit 
from these novel treatment agents, an early diagnosis is 
required.
While efforts have been made to study the symptom 
pathways leading to IPF diagnosis, identifying IPF patients 
using diagnosis codes alone may erroneously include 
patients with other conditions.20 Thus, this study was 
conducted to characterise the pattern of signs, symptoms 
and other clinical predictors preceding IPF diagnosis 
using a real- life population of patients and more defini-
tive selection criteria for IPF.
MethODs
study design
This was a real- life historical cohort study using elec-
tronic medical records from the Optimum Patient Care 
Research Database (OPCRD), a clinical research data-
base containing records of approximately 7 million 
patients from over 700 primary care centres across the UK 
(http:// opcrd. co. uk/)21 with linked patient- completed 
asthma questionnaire. Asthma outcome measures within 
the OPCRD have been validated against patient- reported 
outcomes and treatment response.22 The study was 
conducted according to the quality standards suggested 
for observational studies,23 including the use of an a 
priori analysis plan, study registration with a commitment 
to publish and a well- maintained and monitored study 
database.
Case definition and inclusion criteria
The inclusion criteria for this study were: between 30 to 
100 years of age at diagnosis date, diagnosis date between 
2010 and 1st May 2017, and the diagnosis date must have 
occurred at least 1 year after registration at a participating 
general practice (GP). Patients were excluded if they had 
a code for sarcoidosis, allergic alveolitis, pneumoconiosis, 
asbestosis or other causes of pulmonary fibrosis. The diag-
nosis date was defined as the date of the first IPF diag-
nosis or prescription for IPF- specific pharmacotherapy 
(pirfenidone or nintedanib). The primary analysis popu-
lation includes patients who had a code for a consultation 
with a chest specialist prior to the IPF diagnosis. Selection 
of patients for analyses is further detailed in the online 
supplementary data.
Outcome assessments
The primary outcome of this study was the presence of 
signs and symptoms in the 1 year prior to IPF diagnosis. 
The secondary outcomes of this study were: (1) the consul-
tation rates for the signs and symptoms up to 7 years prior 
to diagnosis, (2) the proportion of patients with respira-
tory consultations and respiratory tests conducted within 
90 and 365 days prior to the chest specialist consultation 
preceding IPF diagnosis and (3) the relationship between 
the signs and symptoms.
Respiratory consultation was identified based on the 
presence of Read codes for the following clinical features: 
chest/respiratory infection, chest symptom, clubbed 
fingers, cough, crackles, dyspnoea or sputum. Respiratory 
tests were identified via Read codes for chest X- ray, chest 
CT scan, lung function test and chest examination.
The Read codes and free- text terms for signs, symp-
toms and clinical features investigated in this study were 
selected via an initial round of manual review of patient 
records. The methods for the selection and the list of 
Read codes and free- text terms are elaborated in the 
online supplementary data.
statistical analysis
For all data handling, statistical analyses and figures Stata/
SE V.14.2 and Stata/MP/6 V.15.1 were used. Descriptive 
statistics were used for baseline characteristics. Contin-
uous variables were summarised as mean (SD) or median 
(IQR) of non- missing observations while categorical 
variables were presented as proportions of non- missing 
observations.
Prevalence of signs and symptoms identified via both 
Read codes and free- text in the 1 year prior to IPF diag-
nosis were presented as number (%). Descriptive statistics 
were also produced for the number of patients with respi-
ratory consultations and tests conducted within 90 days 
and within 365 days prior to the chest specialist consulta-
tion preceding the diagnosis date.
Principal component analysis with rotation was utilised 
to visualise the prevalence and co- occurrence of codes for 
signs, symptoms and other clinical features 90 and 365 
days prior to IPF diagnosis in a network plot. All signs 
and symptoms co- occurrence patterns in the year prior 
diagnosis were also presented as a table.
Consultation rates for signs and symptoms from up 
to 7 years prior to IPF diagnosis were generated and 
expressed as rates per 100 patient- years with 95% CIs. 
For each year, only patients who had a complete year 
of available data contributed to the frequency statistics. 
The number of patients with at least a certain recording 
frequency (recording dates/year, in the period of up to 
12 years before IPF diagnosis) was also tabulated. Data 
are shown for, on average, once a year, once every 2, 3 
and 4 years.
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Figure 1 Flowchart of patient selection. †Code for a 
consultation to a chest specialist followed by an IPF 
diagnosis (code for consultation allowed until up to 60 days 
after diagnosis). *Patients with registration date before date of 
birth. GP,general practice; IPF, idiopathicpulmonary fibrosis; 
OPCRD, Optimum Patient Care Research Database.
Table 1 Baseline demographic patient characteristics and 
procedures (n=462)
Variable Frequency*
Age (years)
  Mean (SD) 74.6 (9.6)
  Median (IQR) 75.0 (69.0 to 81.0)
Male gender 272 (58.9)
BMI
  n (% non- missing) 442 (95.7)
  <18.5 10 (2.3)
  18.5 to <25 137 (31.0)
  25 to <30 163 (39.8)
  ≥30 132 (29.9)
Smoking status
  n (% non- missing) 438 (94.8)
  Current smoker 43 (9.8)
  Ex- smoker 236 (53.9)
  Never smoked 159 (36.3)
Asthma diagnosis† 24 (5.2)
COPD diagnosis† 19 (4.1)
Respiratory tract cancer 0 (0.0)
Other chronic respiratory diseases 
(excluding cancer)‡
4 (0.9)
Lung function test conducted
  90 days prior diagnosis 88 (19.0)
  365 days prior diagnosis 160 (34.6)
*Numbers are presented as n (%) unless specified.
†First diagnostic code recorded ever prior and up to diagnosis 
date.
‡Listed in the online supplementary data.
BMI, body mass index; COPD, chronic obstructive pulmonary 
disease.
Time- course of signs, symptoms and weight measurement 
of individual patients was plotted to visualise the disease 
progression patterns up to 12 years leading to IPF diag-
nosis. Visual evaluation was used to quantify the number of 
patients with each symptom progression pattern.
Descriptive analysis for the mean (SD) time in years 
between the first recorded cough and dyspnoea until the 
diagnosis of IPF was conducted for patients with at least 
1 year medical record history before first symptom available 
and had their symptoms occurring before the IPF diagnosis. 
The cumulative probability of IPF diagnosis every year since 
the first symptoms is presented in the form of life tables and 
Kaplan- Meier plots.
In a sensitivity analysis, all analyses were repeated in 
an overall IPF patients group consisting of patients with 
Read codes or free- text mention for IPF diagnosis and/
or medication (detailed in the online supplementary 
data). For this group, the proportions of patients with 
respiratory consultations and tests were analysed prior to 
the date of IPF diagnosis or chest consultation (which-
ever came first).The study protocol was registered with 
the European Network of Centres for Pharmacoepide-
miology and Pharmacovigilance (ENCePP, registration 
number EUPAS20994).24
Patient and public involvement
This study does not involve patients. The public was not 
invited in the design of the study nor the writing of this 
document.
results
Patients
The patient selection flow is depicted in figure 1. A total 
of 1166 patients were identified to have IPF diagnosis or 
IPF- related medication following inclusion and exclusion 
criteria (overall IPF patient group). Of these, 462 patients 
had a consultation with a chest specialist prior to their IPF 
diagnosis (primary analysis group).
Of the 462 patients, 58.9% were male with a mean 
age at the time of diagnosis was 75 years (table 1). The 
majority (63.7%) of patients had a history of smoking, 
with 9.8% being current smokers. A total of 88 (19.0%) 
patients had spirometry recorded within 90 days and 160 
(36.4%) within 365 days prior to IPF diagnosis. Baseline 
demographics for the overall IPF patient group (n=1166) 
were similar (online supplementary table E1).
Primary outcome: signs and symptoms in the 1 year prior to 
IPF diagnosis
Of the investigated signs and symptoms, cough and 
dyspnoea were the most common symptoms recorded in 
the 1 year prior to IPF diagnosis: cough in 189 (40.9%) 
and dyspnoea in 225 (48.7%) patients (table 2). The 
majority of the patients with cough (58.0%) and dyspnoea 
(55.0%) had more than one recording of the respective 
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Table 2 Signs and symptoms in the 1 year prior to IPF 
diagnosis (n=462)
Signs and symptom N (%)
Dyspnoea 225 (48.7)
Cough* 189 (40.9)
Fatigue or malaise 22 (4.8)
Weight loss 19 (4.1)
Crackles 14 (3.0)
Loss of appetite 13 (2.8)
Clubbed fingers 2 (0.4)
Symptom combinations n (%)
Cough and dyspnoea 108 (23.4)
Dyspnoea without cough 117 (25.3)
Cough without dyspnoea 81 (17.5)
*Of which 25 were ‘dry cough’.
IPF, idiopathic pulmonary fibrosis.
Table 3 History of respiratory consultation and tests before 
chest specialist consultation prior to IPF diagnosis*
Respiratory consultation†
  Within 90 days 238 (51.5)
  Within 365 days 360 (77.9)
Respiratory tests conducted‡
  Within 90 days 176 (38.1)
  Within 365 days 283 (61.3)
*Frequency expressed as n (%).
†Codes for chest/respiratory infection, chest symptoms, clubbed 
fingers, cough, crackles, dyspnoea, or sputum or wheeze.
‡Codes for chest X- ray, chest CT scan, lung function test and 
chest examination.
IPF, idiopathic pulmonary fibrosis.
symptoms in the 1- year period prior diagnosis. Other signs 
and symptoms were rarely observed as the first recorded 
signs and symptoms (<5%). Cough and dyspnoea co- oc-
curred on 23.4% of the patients. The expected rate for 
both symptoms to co- occur, based on the individual rates, 
was 20.0% (95% CI 18.1% to 21.9%). This was not signifi-
cantly different from the observed co- occurrence rate 
(23.4% (95% CI 21.4% to 25.4%)), suggesting both symp-
toms occurred independently of each other.
Detailed results including signs and symptoms identi-
fied via Read codes only, as well as signs and symptoms in 
the overall IPF patients, are presented in online supple-
mentary table E2. Compared with using Read codes only, 
the addition of free- text data increased the number of 
patients with cough by 8.6% and dyspnoea by 13.6%.
secondary outcome: history of respiratory consultation and 
respiratory test prior to chest specialist consultation
Around three- quarters of (77.9%) patients had a respira-
tory primary care consultation recorded in the 365 days 
before their chest specialist consultation (table 3). Respi-
ratory tests were recorded in 61.3% patients in the 365 
days prior to the specialist consultation, and more than a 
third of that (38.1%) was within a 90 days period. Preva-
lence of the components of respiratory consultation and 
respiratory tests are presented in online supplementary 
table E3
The proportions of overall IPF patients with respiratory 
consultations and tests are presented in online supple-
mentary table E4.
secondary outcome: relationship between signs and 
symptoms
The network plots in figure 2 depicts the relationship 
between signs and symptoms recorded in the 90 days and 
in the 365 days prior to IPF diagnosis. Strong associations 
were observed between cough and dyspnoea, and among 
weight loss, loss of appetite and fatigue/malaise. These 
two clusters of symptoms were more pronounced in the 90 
days period compared with in the 365 days period. Within 
the extended list of codes which includes clinical features, 
chest infection was identified to be associated with the 
cough and dyspnoea cluster. However, chest symptoms, 
a category containing unspecified chest symptoms, chest 
examinations and chest CT and X- rays, were more closely 
associated with the fatigue/malaise cluster. Similar results 
were observed within the overall IPF patient population 
(online supplementary figure E1).
The prevalence of every symptom combination within 
1 year prior to IPF diagnosis is shown in table 4. No symp-
toms were recorded in 30.7% of the patients. The most 
common symptom pattern was dyspnoea alone (22.9%), 
cough with dyspnoea (16.5%) and cough alone (13.9%). 
Other symptom combinations were rarely observed (≤2% 
patients). Symptom combinations in the overall IPF 
patients are shown in online supplementary table E5.
The frequencies of codes for signs and symptoms 
up to 7 years leading to the IPF diagnosis are shown in 
figure 3. A rapid rise in the consultation rate for cough 
and dyspnoea occurred in the year prior to IPF diagnosis, 
but the increase in cough and dyspnoea started 4 to 5 
years before diagnosis. A similar pattern was observed for 
consultation for concurrent cough and dyspnoea. This 
rise was not observed in the other, less common signs and 
symptoms. The frequencies of codes for signs and symp-
toms in the overall IPF group are shown in online supple-
mentary figure E2.
The number of patients with at least a certain average 
symptom frequency in the period before IPF diagnosis 
(up to 12 years) are presented in online supplementary 
table E6.
symptom progression patterns preceding IPF diagnosis
Several typical patterns of patient pathways were iden-
tified from visual assessment of individual patient time-
lines; cough tended to precede dyspnoea. Weight loss, 
observed via weight measurements over time, commonly 
followed recordings of cough and dyspnoea. 244 of the 
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Figure 2 Principal component analysis based network chart for the association between codes within 90 and within 365 days 
prior to IPF diagnosis. Bubble size indicates prevalence, and thickness of lines indicate the degree of association between signs 
and symptoms. COPD,chronic obstructive pulmonary disease; ILD, interstitial lung disease; IPF,idiopathic pulmonary fibrosis.
462 (52.8%) patients had ≥4 records of weight in the 
previous 5 years, and of these, 116 (47.5%) recorded 
weight loss of more than five kilograms. The weight loss 
often occurred over at least 5 years period (example from 
two patients in figure 4), however, acute weight loss was 
also observed (online supplementary figure E3).
Other examples of identified patterns are presented 
in online supplementary figure E4. A minority, 69 out of 
462 (14.9%), received a diagnosis without any symptom 
codes in the preceding years. Many patients had no clear 
pattern of respiratory symptoms or weight loss.
Probability of IPF diagnosis from the first recording of 
symptoms
Analysis of probability for IPF diagnosis since the first 
recorded symptom of cough or dyspnoea included 463 
patients (322 and 293 patients with cough and dyspnoea, 
respectively). The mean (SD) time since the first cough 
was longer (6.3 (5.5) years) compared with since the first 
dyspnoea (4.3 (4.3) years). Cumulative probability of IPF 
diagnosis since the first recording of symptoms is illus-
trated as a life table (online supplementary table E7) and 
a Kaplan- Meier plot (online supplementary figure E5). 
These show that 50% of the patients are diagnosed within 
5 years from their first recorded cough, and within 3 years 
from their first recorded dyspnoea. However, it took, 
respectively, 13 and 10 years since their first symptoms for 
90% of the patients to receive an IPF diagnosis.
DIsCussIOn
Main findings
This is a real- life historical cohort study of IPF patients to 
identify the symptoms, signs and clinical features recorded 
before the diagnosis of IPF. Cough and dyspnoea were 
observed to be the most common recorded symptoms in 
the 1 year prior to IPF diagnosis, occurring in above 40% 
of the patients. Other symptoms, such as weight loss and 
fatigue, or signs such as crackles and clubbed fingers were 
rarely observed (<5% patients). The majority of patients 
(77.9%) had a history of at least one primary care respi-
ratory consultation within a year prior to their chest 
specialist consultation preceding the diagnosis of IPF.
A retrospective review of records from up to 7 years 
prior to diagnosis demonstrated an increased frequency 
of codes for cough and dyspnoea starting from 4 to 5 
years prior to IPF diagnosis, which further rose sharply 
nearer to the IPF diagnosis. Thus, repeated consultations 
for prolonged cough and dyspnoea are likely to be the 
characteristic symptoms of IPF.
The symptom combination of cough and dyspnoea 
in the year before IPF diagnosis was observed to be one 
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Table 4 Co- occurrence of signs and symptoms in the 1- year period up to IPF diagnosis
Clubbed 
fingers Cough Crackles
Dry 
cough Dyspnoea
Fatigue or 
malaise
Loss of 
appetite
Weight 
loss Patients % Cumulative %
142 30.7 30.7
106 22.9 53.7
76 16.5 70.1
64 13.9 84.0
9 1.9 85.9
9 1.9 87.9
8 1.7 89.6
5 1.1 90.7
4 0.9 91.6
4 0.9 92.4
3 0.6 93.1
3 0.6 93.7
2 0.4 94.2
2 0.4 94.6
2 0.4 95.0
2 0.4 95.5
2 0.4 95.9
1 0.2 96.1
1 0.2 96.3
1 0.2 96.5
1 0.2 96.8
1 0.2 97.0
1 0.2 97.2
1 0.2 97.4
1 0.2 97.6
1 0.2 97.8
1 0.2 98.1
1 0.2 98.3
1 0.2 98.5
1 0.2 98.7
1 0.2 98.9
1 0.2 99.1
1 0.2 99.4
1 0.2 99.6
1 0.2 99.8
1 0.2 100.0
Secondary outcome: consultation rate in the years leading to IPF diagnosis.
IPF, idiopathic pulmonary fibrosis.
of the most common symptom co- occurrence patterns. 
Using principal component analysis, we have shown the 
close association between cough and dyspnoea in the 
preceding 90 and 365 days within patients with IPF. Rates 
for consultations for both symptoms also increased 4 to 5 
years prior diagnosis, similar to the coding of individual 
symptoms. Thus, prolonged history or presentation of 
both symptoms is likely to be a ‘red flag’ to consider IPF 
and to refer to specialist respiratory services especially 
when other conditions such as asthma or chronicobstruc-
tive pulmonary disease (COPD) have been ruled out. A 
second cluster between weight loss, loss of appetite and 
fatigue or malaise was identified. However, these signs 
and symptoms were too infrequent and unlikely to be 
helpful for the early identification of IPF in community 
settings.
Surprisingly, 30.7% of our patients were not recorded 
as having any signs or symptoms in the 1 year prior to 
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Figure 3 Frequency of codes for signs and symptoms from 
7 years prior to IPF diagnosis. (A) All signs and symptoms, (B) 
co- occurring dyspnoea and cough, (C) excluding cough and 
dyspnoea. IPF, idiopathic pulmonary fibrosis.
IPF diagnosis (table 4). Analysis of symptom progression 
patterns also showed that 14.9% of the patients did not 
have any symptom codes in the years leading to IPF diag-
nosis. This may be due to a tendency for primary care 
physicians to code for the final diagnosis instead of the 
presenting symptoms during consultations. Alternatively, 
IPF may be diagnosed coincidentally by investigations for 
other conditions, such as cardiac CT scanning, without 
records of respiratory signs and symptoms.
A novelty of the current study is the investigation of 
symptom progression patterns in the years leading to IPF 
diagnosis. Cough symptoms tended to precede dyspnoea. 
However, many of these cough records may have been 
unrelated to IPF, for example, viral infection. Weight 
loss was observed to be a common sequel to cough and 
dyspnoea, occurring over at least 5 years, suggesting the 
possibility of a disease process preceding the diagnosis by 
several years. Many patient pathways had no clear pattern 
of respiratory symptoms or weight loss.
strengths and limitations
A strength of this study is the conduct of initial reviews of 
individual primary care case notes to create the list of Read 
codes and free- text terms. This enabled less commonly 
IPF- related signs, symptoms and clinical features to be 
included within this study, which may have been other-
wise missed if a predetermined list of features and codes 
was used instead.
This study used information from free- text primary 
care records in addition to diagnostic Read codes. The 
usage of information from free- text records increased 
detection sensitivity for signs and symptoms, contributing 
an additional 8.6% patients with symptoms of cough and 
13.6% with dyspnoea in the 1 year prior to IPF diagnosis. 
The recording of respiratory symptoms such as breath-
lessness has previously been found to occur in free- text 
well before specific codes are entered in for people with 
COPD and asthma.25
This study used every eligible patient from a primary 
care records database, with the data availability extending 
to 7 years prior to the diagnosis of IPF. The real- life design 
of this study provides high generalisability of the results 
to primary care patients managed in actual primary care 
practice. Additionally, the long observation period and 
the availability of free- text clinical records demonstrate 
the particular strengths of the OPCRD database for 
longitudinal studies on rare diseases. Clinical records 
within participating GPs also contain records of patients’ 
secondary care usage, allowing identification of patients 
who had previous consultation with a specialist.
In this study, we selected patients who had a consulta-
tion with a chest specialist prior to their diagnosis for anal-
ysis. This group of patients was selected out of concern 
that coding for IPF diagnosis may have been entered as 
a diagnostic query or mistake instead of a definitive diag-
nosis. Indeed, higher rates of cough and dyspnoea were 
observed from both Read codes and free- text in patients 
with specialist consultation prior to IPF diagnosis (online 
supplementary table E2). Potential bias of GP diagnosis 
was also addressed by the additional requirement for 
prior specialist assessment.
The main weakness of this study is our lack of gold stan-
dard diagnostic criteria in many patients as we were unable 
to review the contents of letters from secondary care or 
hospital records directly. Due to this, it is not possible 
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Figure 4 Time course of respiratory symptoms and weight prior to the diagnosis of IPF in two patients showing a long duration 
of weight loss. COPD,chronic obstructive pulmonary disease; ex., exacerbation; examn, examination; f.,fingers; inf., infection; 
IPF, idiopathic pulmonary fibrosis; Loss app., lossof appetite; mal., malaise.
to directly confirm that the diagnoses of IPF were made 
in secondary care, despite the presence of preceding 
consultation with chest specialists. Our additional selec-
tion criterion, requiring prior chest specialist consulta-
tion, also resulted in a reduced sample size. Regardless, 
the pattern of previous respiratory examinations and the 
outcomes observed seem to support the diagnosis of IPF 
within the patients. A further weakness is that the primary 
care records in the OPCRD were initially collected for 
clinical instead of research purposes, thus the coding of 
symptoms may be inconsistent. However, the use of free- 
text searches in this study may mitigate this issue.
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We did not exclude patients with asthma or COPD, 
which may also cause symptoms of cough and dyspnoea. 
We felt that asthma and COPD are both common disor-
ders and misdiagnosis of IPF as either symptom are likely. 
Regardless, the numbers of patients with asthma (n=24) 
and COPD (n=19) are too small to conduct separate anal-
yses and are unlikely to relevantly change our conclu-
sions. The small number of patients with concomitant 
COPD is likely due to the unique requirement of the UK 
primary care system since 2002 in which a diagnosis of 
COPD requires confirmation by spirometry. Consequen-
tially, the UK may have less misdiagnosis of IPF as COPD 
than other healthcare systems.
Placing results in the context of published studies
The observed increase in frequency for cough and/or 
dyspnoea from 5 years prior IPF diagnosis suggests a 
delay between recognition of symptoms and diagnosis. 
Such a delay in the referral and diagnosis of IPF since 
the initial symptom presentation has been observed in 
previous studies.26 27 A multicentre cohort study was 
recently conducted to describe the factors responsible 
for the delay in IPF diagnosis.28 The study reported a 
mean delay of 2.1 years and that the delay can be mainly 
attributed to the patients, general practitioners and 
community hospitals. Due to the importance of early 
diagnosis of IPF,29 there is a need to further under-
stand and rectify the causes for delays in diagnosis and 
referral.
A previous study investigated the prevalence of symp-
toms from up to 5 years before IPF diagnosis using another 
primary care record database in the UK, The Health 
Improvement Network (THIN).20 Similar to our study, the 
study also reported breathlessness and cough, identified via 
Read codes, to be the most common symptoms increasing 
sharply at 1 year prior to IPF diagnosis. However, the study 
relied solely on Read codes (for idiopathic fibrosing alveo-
litis (H563.00), Hamman- Rich syndrome (H563.11), cryp-
togenic fibrosing alveolitis, diffuse pulmonary fibrosis and 
idiopathic fibrosing alveolitis NOS (not otherwise speci-
fied)) to identify patients with IPF. The authors acknowl-
edged that there was a possibility of miscoding leading to 
the inclusion of patients with other fibrotic lung disorders6 
and thus labelled cases within their study as ‘IPF- clinical 
syndrome’ instead of definitive IPF patients. Our current 
study confirmed their finding using a more conservative 
IPF definition (requiring chest specialist consultation prior 
to the diagnosis) which was expected to be more selective 
for patients with actual IPF. The current study also extends 
the previous study by investigating the relationship between 
the signs and symptoms, demonstrating a common co- oc-
currence between cough and breathlessness. Furthermore, 
our study has the additional strength of a longer observa-
tional period prior to IPF diagnosis (7 years) and the util-
isation of free- text clinical records to identify signs and 
symptoms which would have been missed by using only 
Read codes.
COnClusIOns
This is the first study to analyse the presence, association 
and progression patterns of symptoms and clinical features 
leading to IPF diagnosis within a more definitive group of 
patients with IPF, utilising both coded diagnosis and free- 
text primary care records. Cough and dyspnoea represented 
the most common symptoms in the 1 year prior to the diag-
nosis of IPF. Both symptoms were found to be closely asso-
ciated and were likely to co- occur. While the consultation 
rates for cough and dyspnoea rose sharply 1 year preceding 
the diagnosis, the increases in rates were already observable 
from up to 5 years prior to IPF diagnosis. Lastly, the majority 
of the patients had records of respiratory consultations and 
tests conducted prior to their IPF diagnosis.
Taken together, general practitioners should further 
assess the possibility of IPF in patients who have increasing 
consultations for prolonged cough and/or progressive 
dyspnoea, especially if accompanied with weight loss.
Further work will investigate the value of chest X- ray 
and spirometry in predicting subsequent IPF diagnosis. 
Linking data within electronic medical records and regis-
tries such as BLUETEQ database register of UK specialist 
drug prescribing30 and BTS ILD registries for higher quality 
research in IPF is also needed to provide deeper insight 
into the patterns of disease progression identified in this 
study. Further research comparing the clinical pathway 
of IPF patients with a control group of patients, as well as 
investigating whether spirometry led to a timelier referral 
to specialists may also be warranted.
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